Cancer Research and Treatment

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing

Bradley M. Turner, Brian S. Finkelman, David G. Hicks, Numbere Numbereye, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Mary Ann G. Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, Hani Katerji, Huina Zhang

Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component

Yufei Zeng, Weiqi Gao, Xiaosong Chen, Kunwei Shen

British Journal of Cancer.2021; 124(5): 975. CrossRef

Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Simon Gagnet, Caroline Diorio, Louise Provencher, Cynthia Mbuya-Bienge, Julie Lapointe, Claudya Morin, Julie Lemieux, Hermann Nabi

Journal of Personalized Medicine.2021; 11(9): 858. CrossRef

Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach

Bradley M. Turner, Hani Katerji, Huina Zhang, David G. Hicks

Human Pathology Reports.2021; 26: 300574. CrossRef

Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer

Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim, Seock-Ah Im

Clinical Breast Cancer.2020; 20(2): 98. CrossRef

Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer

Yufei Zeng, Weiqi Gao, Lin Lin, Xiaosong Chen, Kunwei Shen

Journal of Geriatric Oncology.2020; 11(5): 843. CrossRef

Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters

The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool

Anna Olsson-Brown, Pavlos Piskilidis, Julie O'Hagan, Nicky Thorp, Peter Robson, Helen Innes, Helen Wong, Silvia Cicconi, Richard Jackson, Tamara Kiernan, Christopher Holcombe, Susan O'Reilly, Carlo Palmieri

Clinical significance of 21-gene recurrence score assay for hormone receptor–positive, lymph node-negative breast cancer in early stage

Yang Yu-qing, Wang Lei, Huang Mei-ling, Xiao Jing-jing, Wei Mei-chen, Wu Jiang, Hao Jun-sheng, Ling Rui, Li Nan-lin

Experimental and Molecular Pathology.2019; 108: 150. CrossRef

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis

Sue Harnan, Paul Tappenden, Katy Cooper, John Stevens, Alice Bessey, Rachid Rafia, Sue Ward, Ruth Wong, Robert C Stein, Janet Brown

Health Technology Assessment.2019; 23(30): 1. CrossRef

Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor−Positive Breast Cancer

Megan C. Roberts, Allison W. Kurian, Valentina I. Petkov

Journal of the National Comprehensive Cancer Network.2019; 17(6): 662. CrossRef

Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30

Seho Park, Yunan Han, Ying Liu, Adetunji T. Toriola, Lindsay L. Peterson, Graham A. Colditz, Seung Il Kim, Young Up Cho, Byeong-Woo Park, Yikyung Park

Breast Cancer Research.2019;[Epub] CrossRef

Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer

Lizhe Zhu, Nan Ma, Bin Wang, Can Zhou, Yu Yan, Ke Wang, Jianjun He, Yu Ren

Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe

E.J. Blok, E. Bastiaannet, W.B. van den Hout, G.J. Liefers, V.T.H.B.M. Smit, J.R. Kroep, C.J.H. van de Velde

Cancer Treatment Reviews.2018; 62: 74. CrossRef

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer

Jae-Myung Kim, Jai Min Ryu, Isaac Kim, Hee Jun Choi, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Se Kyung Lee, Jeong Eon Lee

Journal of Breast Cancer.2018; 21(2): 222. CrossRef

Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay

Soo Jin Park, Moo Hyun Lee, Sun-Young Kong, Mi Kyung Song, Jungnam Joo, Youngmee Kwon, Eun-Gyeong Lee, Jai Hong Han, Sung Hoon Sim, So-Youn Jung, Seeyoun Lee, Keun Seok Lee, In Hae Park, Eun Sook Lee

Breast Cancer Research and Treatment.2018; 170(1): 69. CrossRef

Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores

Jonathan Chen, Xian Wu, Paul J. Christos, Silvia Formenti, Himanshu Nagar

Breast Cancer Research.2018;[Epub] CrossRef

Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer

Jai Min Ryu, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Jee-Eun Kim, Byeong-il Kang, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim

Breast Cancer Research and Treatment.2018; 172(3): 627. CrossRef

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit

Impact d’un test de signature génomique en sénologie sur les décisions en réunion de concertation pluridisciplinaire : une expérience française

C. Dreyfus, M. Ballester, J. Gligorov, P. Agranat, M. Antoine, I. Tengher, A. Bricou

Gynécologie Obstétrique & Fertilité.2015; 43(12): 780. CrossRef